Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ

Great Lakes Advisors LLC acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 33,804 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,146,000. Great Lakes Advisors LLC owned about 0.05% of Jazz Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of JAZZ. USA Financial Formulas purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth about $25,000. LRI Investments LLC bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $38,000. Danske Bank A S purchased a new position in Jazz Pharmaceuticals in the third quarter valued at about $40,000. Geneos Wealth Management Inc. grew its position in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total value of $1,517,880.00. Following the completion of the sale, the director owned 360,682 shares of the company’s stock, valued at $91,245,332.36. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the sale, the executive vice president directly owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 19,098 shares of company stock worth $4,649,786 over the last ninety days. Insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on JAZZ. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $287.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $280.00 to $283.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Finally, UBS Group restated a “buy” rating and issued a $315.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $272.89.

Jazz Pharmaceuticals Stock Down 0.4%

JAZZ stock opened at $252.16 on Thursday. The company’s 50 day moving average is $244.06 and its 200 day moving average is $214.43. The stock has a market cap of $16.37 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 1-year low of $118.04 and a 1-year high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same period last year, the firm earned ($8.25) EPS. The company’s revenue for the quarter was up 15.5% on a year-over-year basis. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 21.66 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.